Skip to main content
. 2021 Jul 2;4:834. doi: 10.1038/s42003-021-02352-2

Fig. 1. Overview of BMS-PRISM platform.

Fig. 1

Solid tumor cell lines were individually infected with Cas9 and 26-bp barcode and tested for CRISPR editing efficiency before archived into BMS-PRISM library. These engineered cell lines were then subpooled and banked according to cancer indications for convenient handling. A full or focused collection of cell lines can be used for the compound as well as CRISPR/Cas9 knockout screening to evaluate drug response or gene essentiality in a single run. Relative cell line abundance after various treatments can be determined by PCR amplification of barcodes and next-generation sequencing.